Abstract
The morphologies of homoharringtonine were conveniently controlled by solvent treatment and the morphologies of homoharringtonine were characterized by XRD and SEM. Crystalline homoharringtonine was simply made by dissolving homoharringtonine in a special polar solvent containing a small amount of water (methanol/water= 98/2, v/v). On the other hand, amorphous homoharringtonine was made by dissolving homoharringtonine in relatively non-polar solvent (methylene chloride/methanol=98/2, v/v). Amorphous homoharringtonine, with a fine particle size, was obtained by dissolving in methylene chloride/methanol (98/2, v/v), following by spray drying. Also, residual solvents, methanol and methylene chloride, were easily removed to less than concentration limit in ICH (International Conference on Harmonisation) guidance by spray drying and successive drying in a vacuum oven. Amorphous homoharringtonine was more soluble in water than crystalline homoharringtonine, and the water content of amorphous homoharringtonine was less changeable than crystalline homoharringtonine at given humidity (95 RH%) during storage. This information is very useful for production and quality control of pharmaceuticals in the commercialization step.
This is a preview of subscription content, log in via an institution to check access.
References
J. L. Grem, B. D. Cheson, S. A. King, B. Leyland-Jones and M. Suffness, J. Natl. Cancer Inst., 80, 1095 (1988).
J. He, A. P. Cheung, E. Wang, E. Struble, K. Fang, N. Nguyen and P. Liu, J. Pharm. Biomed. Anal., 22, 541 (2000).
J. Jin, D. Z. Jiang, W.Y. Mai, H. T. Meng, W. B. Qian, H. Y. Tong, J. Huang, L. P. Mao, Y. Tong, L. Wang, Z. M. Chen and W. L. Xu, Leukemia, 3, 1361 (2006).
W. Z. Xie, M. F. Lin, H. Huang and Z. Cai, Am. J. Chin. Med., 34, 233 (2006).
C. Y. Luo, J. Y. Tang and Y. P. Wang, Hematology, 9, 259 (2004).
D. C. Zhou, R. Zittoun and J. P. Marie, Bull. Cancer, 82, 987 (1995).
D. Marin, J. S. Kaeda, C. Andreasson, S. M. Saunders, M. Bua, E. Olavarria, J. M. Goldman and J. F. Apperley, Cancer, 103, 1850 (2005).
G. Visani, D. Russo, E. Ottaviani, P. Tosi, D. Damiani, A. Michelutti, S. Manfroi, M. Baccarani and S. Tura, Leukemia, 11, 624 (1997).
S. O’Brien, F. Giles, M. Talpaz, J. Cortes, M. B. Rios, J. Shan, D. Thomas, M. Andreeff, S. Kornblau, S. Faderl, G. Garcia-Manero, K. White, S. Mallard, E. Freireich and H. M. Kantarjian, Cancer, 98, 888 (2003).
T. Efferth, M. Davey, A. Olbrich, G. Rucker, E. Gebhart and R. Davey, Blood Cells Mol. Dis., 28, 160 (2002).
H. M. Kantarjian, M. Talpaz, V. Santini, A. Murgo, B. Cheson and S. M. O’Brien, Cancer, 15, 1591 (2001).
L. Keller, F. Dumas and J. d’Angelo, Tetrahedron Lett., 42, 1911 (2001).
B. S. Kim and J. H. Kim, Korean J. Chem. Eng., 25, 108 (2008).
W. L. Chiou and S. Riegelman, J. Pharm. Sci., 60, 1281 (1971).
J. H. Kim, Korean J. Biotechnol. Bioeng., 21, 1 (2006).
S. S. Park and H. Y. Kang, Korean J. Chem. Eng., 25, 78 (2008).
U. S. Sharma, S. V. Baulausbramanaian and R. M. Straubinger, J. Pharm. Sci., 84, 1223 (1995).
ICH guidance Q3C impurities: Residual solvents, Federal register, 62(247), 67378 (1997).
B. C. Hancock and M. Parks, Pharm. Res., 17, 397 (2000).
U. S. Gi, B. Min, J. H. Lee and J. H. Kim, Korean J. Chem. Eng., 21, 816 (2004).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, BS., Kim, JH. Characterization of solvent induced crystalline and amorphous homoharringtonine. Korean J. Chem. Eng. 26, 1090–1093 (2009). https://doi.org/10.1007/s11814-009-0181-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11814-009-0181-z